

An update on diagnosis and treatment of adult growth hormone deficiency

Orsalia Alexopoulou, Dominique Maiter

Mise à jour sur le diagnostic et le traitement de la déficience en hormone de croissance chez l'adulte

La déficience en hormone de croissance de l'adulte (AGHD) est reconnue aujourd'hui comme un syndrome clinique à part entière et son traitement est devenu une pratique courante. Les bénéfices du traitement l'emportent sur les risques potentiels mais certains sujets concernant l'efficacité du traitement à long-terme et la sécurité restent débattus. Dans certains domaines clés, de nouvelles études sont nécessaires et une surveillance longitudinale des patients traités par hormone de croissance est indispensable.

MOTS-CLÉS

Déficience en Hormone de croissance, insuffisance antéhypophysaire, adultes avec déficit en GH

Adult growth hormone deficiency (AGHD) is nowadays recognized as a distinct clinical entity and replacement therapy has become a standard practice. The benefits of GH treatment seem to outweigh its potential risks but issues concerning long term efficacy and safety are still a subject of debate. More research is needed in some key areas and it remains essential to monitor patients by means of longitudinal surveillance studies.

INTRODUCTION

The isolation and purification of cadaveric pituitary derived growth hormone (GH) occurred in the late 50's (1). In 1959 Raben reported the results of the first trial showing the effects of human GH on growth (2). During the two next decades GH was used primarily for the treatment of childhood growth retardation and its use was restricted by the limited supply of the pituitary-extracted hormone. A valid radioimmunoassay for detection of plasma GH was published in 1963, which identified significant amounts of circulating GH in healthy adults, thereby supporting the idea of a meaningful biological role (3). After the withdrawal of the pituitary extracted native hormone in 1985, following alarming reports of several cases of Creutzfeldt-Jakob disease (4), the introduction of recombinant human GH (rhGH) in 1985 provided an opportunity for further studies of its effects in adults. The first double-blind, randomized placebo controlled trials investigating the effects of GH in adults were completed in 1989 (5,6) and gave the impetus to a huge scientific craze leading to a plethora of publications on a new syndrome called 'Adult Growth Hormone Deficiency' (AGHD). The rational use of GH as replacement therapy in the adult was thus progressively established and today AGHD is universally recognized as a true clinical syndrome and its treatment has become standard practice (7).

Although rhGH has been used for almost 30 years and the benefits of treatment seem to outweigh its potential risks, issues concerning long term efficacy and safety are still a subject of debate. With this in mind we will discuss here the main aspects of AGHD 25 years after its first use in our country and try to answer when and why it is still worth to treat adults with this GH deficiency syndrome.

AETIOLOGY

Growth hormone deficiency (GHD) can develop due to a variety of conditions and may present during childhood or adulthood (**Table 1**). The aetiologies of adult GH deficiency are almost identical to those of hypopituitarism. More than two-thirds of cases are caused by pituitary adenomas or other tumors of the sellar region, or result from the treatment of such tumors (8, 9). Congenital GHD may be isolated or associated with other pituitary hormone deficiencies. In the majority of cases, no cause can be identified and they are classified as idiopathic (10). Idiopathic GH deficiency arising in adult life is rare and its diagnosis requires rigorous testing (11). Traumatic brain injury (TBI) has been recently documented as a frequent cause of GHD (12). Childhood onset GH deficiency due to an organic cause will almost always persist into adulthood while patients with idiopathic isolated GHD could often have no more biochemical criteria for AGHD when retested in adult life and therefore will not need to restart GH treatment as adults (13, 14).

Table 1. Main causes of adult growth hormone deficiency (AGHD)

Childhood onset
Congenital - Idiopathic - Genetic - Associated with embryologic defects Cranial irradiation for brain tumor, lymphoma, leukaemia Head trauma Central nervous system tumors Infiltrative diseases
Adulthood onset
Pituitary/hypothalamic tumors and their treatment Peri-sellar tumors (craniopharyngioma, meningioma, chordoma, etc...) Brain injury/subarachnoid haemorrhage Sheehan's syndrome Autoimmune lymphocytic hypophysitis or any other cause of hypophysitis (IgG4-related, ipilimumab-related...) Infiltrative/ granulomatous/infectious diseases Empty sella syndrome Idiopathic

DIAGNOSIS OF ADULT GH DEFICIENCY

AGHD should be investigated in patients with a high pre-test probability of having the disease and in whom there is a medical indication and patient willingness to start treatment if needed (7). True AGHD syndrome should

not be confused with states of functional and relative GH insufficiency, such as obesity and aging. It is important to mention that the normal progressive decrease of GH secretion with aging (the so called "somatopause") is not a recognized indication for GH treatment and substantial evidence suggests that GH use in the healthy elderly is associated with little benefits and increased rates of adverse events (15,16).

Therefore, the investigation of adult patients for GH status should be limited to specific cohorts of GHD candidates(7,11).

- Young adult patients with a history of childhood GHD should be retested to confirm GHD after completion of growth. However, retesting during the transition period is not mandatory in patients expected to have lifelong severe GHD owing to causes such as genetic mutation, structural lesions or multiple pituitary hormone deficiencies (17,18).
- Patients harboring a known organic hypothalamic-pituitary lesion.
- Patients with a history of surgery or radiation therapy of a pituitary or brain lesion. Total body irradiation even at low doses (10-12 Gy) can induce GHD several years later (19).
- Patients with a history of head trauma or subarachnoid hemorrhage.
- Patients with clinical and/or biochemical evidence of other pituitary hormone deficits - (as these can be diagnosed lately after an initial asymptomatic pituitary disease such as Sheehan's syndrome)

BIOCHEMICAL TESTING FOR AGHD

The symptoms and signs of GH deficiency in adults are non specific (**Table 2**). Biochemical testing to assess GH production is therefore essential for diagnosis. Because GH secretion is pulsatile (20), a single serum GH measurement will not accurately reflect appropriate somatotrophic function (11,21). On the other hand IGF-I has a long half-life in the circulation, but measurements of IGF-I are of limited utility in diagnosing GH deficiency in adults because of considerable overlap in plasma IGF-I levels between individuals with and without GHD (22). However in patients with organic or genetic cause of severe GHD, a very low serum IGF-I associated with deficiencies in three or more other pituitary hormones is as specific for the diagnosis of GH deficiency as any available provocative test (18).

The diagnosis of growth hormone deficiency must be confirmed by an abnormal hormonal response to one or more provocative tests. Several tests have been studied and the insulin tolerance test (ITT) is still the 'gold standard' or reference test but it requires medical surveillance and is contraindicated in patients with ischemic heart disease, seizure disorders and is a potential risk in elderly patients (7,17). The glucagon test and the combined GHRH-arginine test are considered valid alternatives. The cut-off values for optimal sensitivity and specificity vary

Table 2. Main symptoms and signs of adult growth hormone deficiency (AGHD)

• Chronic fatigue/psychosocial problems/decreased quality of life
• Fine and dry skin
• Increased truncal adiposity/decreased lean body mass
• Reduced muscle strength and exercise capacity/ impaired cardiac function
• Decreased bone mineral density (BMD) and increased risk of fracture
• Atherogenic lipid profile/increased pro-inflammatory markers/increased intima-media thickening/insulin resistance

among the commonly used tests (23). For the insulin and glucagon tests, the threshold value defining severe GH deficiency is 3 µg/L, whereas partial deficiency is defined by a peak between 3.01 and 5 µg/L. For the GHRH-arginine test different threshold according to BMI have been proposed: <11.5 µg/L for BMI<25kg/m², <8 µg/L for BMI of 25-30 kg/m² and 4.2 µg/L for those with a BMI >30 kg/m². (24). Recently a lower threshold of 1 µg/L has also been proposed for glucagon test in overweight/obese subjects, as obesity naturally blunts GH response to glucagon stimulation (25).

TREATMENT OF GH DEFICIENCY

BENEFITS OF GH REPLACEMENT THERAPY

During the past 30 years, many clinical studies have investigated the short- and long-term effects of GH replacement in patients with AGHD.

The most consistent finding across studies of GH replacement therapy is improvement in body composition with an increase in lean body mass (LBM) and a decrease in total body fat (BF) (26, 27). These effects are rapid, occurring during the first 3 months of treatment and are maintained over 15 years (28), even though the treatment cannot prevent the modifications of body composition related to ageing (29, 30). Results on long-term effects on BMI appear to be inconclusive (27). As GH replacement increases lean body mass one might expect an improvement of muscle function as well, but data are rather conflicting (31,32).

The positive effects of GH therapy on bone mass and bone mineral density (BMD) in AGHD patients are undeniable and are only observed after at least 18-24 months of treatment. GH replacement therapy results in a biphasic change in BMD, with an initial 6-12 month period of increased bone resorption followed by an overall increase

in bone mass (27). These effects are affected by gender, age and treatment duration (33). Prospective studies of long duration show that GH replacement for up to 15 years leads to a significant increase in BMD in the lumbar spine, particularly in men, and to stabilization of BMD values at the femoral neck (34, 35). However there is still scarce evidence that prolonged AGHD replacement ultimately reduces the risk of fractures (36-38). In particular, randomized controlled clinical trials with fracture end points are still not available and would be needed in order to definitively establish a protective effect of GH therapy.

Patients with hypopituitarism have reduced life expectancy, with a 2-fold higher risk of death from cardiovascular disease compared with healthy controls (39, 40). GH deficiency is the most likely explanation for this finding (41) although other factors such as underlying pathology, previous radiotherapy, and over- or under-replacement of other pituitary hormones may also been implicated (39, 40). There is growing body of evidence indicating that patients with adult GH deficiency are characterized by a cluster of different cardiovascular risk factors and markers, which can significantly increase their cardiovascular morbidity and mortality (42-44).

Prolonged GH therapy improves several cardiovascular risk factors, particularly the lipid profile. A meta-analysis of blinded, randomized, placebo-controlled trials showed that GH replacement has beneficial effects on body composition, total and LDL cholesterol levels as well as on diastolic blood pressure (45). We nowadays know that these effects are sustained and persist after 15 years of treatment (28). Furthermore, additional benefits on serum lipid levels may be achieved by a combination therapy of GH and statin (46). GH may also have beneficial effects on other cardiovascular risk factors, such as fibrinogen and inflammatory parameters, and reduce the intima-media thickness of the carotid arteries (45, 47, 48). The effects of GH on cardiac function have also been investigated and the most consistent effects are increases in left ventricular mass, wall thickness, left ventricular end-diastolic diameter and volume of blood ejected at each systole (49). However, the global benefit of GH replacement on clinical endpoints, such as cardiovascular disease morbidity and mortality remains to be determined in larger prospective and long-term studies.

The effects on glucose metabolism are more complex. As expected GH acutely reduces insulin sensitivity but these deleterious effects are not maintained after prolonged therapy and after a few years of treatment insulin resistance improves, probably as a consequence of the favorable modifications of the body composition (45, 50). Nonetheless, a proportion of AGHD patients will develop type 2 diabetes with increasing duration of GH replacement and increasing age, especially in the presence of predisposing conditions such as obesity or pre-existing glucose intolerance (28, 51).

Growth hormone deficiency in adults causes distress and poor well-being. Patients with AGHD often complain of chronic fatigue and feel less energetic and less healthy than normal subjects of the same age (52). A disease

specific questionnaire (AGDA-QoL) has been developed and validated for evaluating the quality of life in AGHD patients (53). It comprises 25 items based on the symptoms most frequently reported by GHD adults. Numerous placebo-controlled, double blinded studies as well as cohort studies have documented significant improvements in QoL scores and psychological well-being under GH therapy in most, but not all, adults with GH deficiency who had impaired QoL at baseline assessment (27,54-56). Most of the improvement in QoL occurs during the first year of treatment and data from long term trials demonstrate a sustained improvement for at least 10 years, with the most marked improvements in GHD women and in patients with low baseline QoL (57, 58). In addition GH replacement therapy results in a significant decrease in the number of days of "sick leave", the number of days at hospital and the number of visits to the doctor (59). This indirectly demonstrates an improvement in the overall health state of GH-treated adult subjects, and should be considered when calculating the socio-economic cost of treatment.

OPTIMAL DOSE AND MONITORING OF GH THERAPY

Initially, GH doses were determined based on weight or surface area, in analogy with the experience gained from pediatric practice (5, 6). This approach resulted in GH doses of approximately 25 µg/kg that were associated with supra-normal levels of serum IGF-I and high rates of side effects (60). Current treatment regimens use individualized, weight independent dose-titration approach, taking into account the patient's age, sex and estrogen status (7). In order to avoid adverse events, treatment is initiated with low doses which are progressively up-titrated to attain normal IGF-I levels (7). Although serum IGF-I cannot be assumed to reflect the overall effect of GH in all tissues, it remains the most useful serum marker for GH dose titration in adults (7, 60, 61). The common target used for IGF-I is the upper half of the reference range, unless side effects are present but in elderly patients the target IGF-I range could considerably be reduced (7, 61). Daily subcutaneous injections might be responsible of poor adherence that increases over time and compromises therapeutic efficacy. In the last few years new long-acting GH preparations have been developed, showing similar clinical effects in comparison with daily GH injections (62,63). However, a recent review by an expert panel (64) concluded that, as these formulations have different pharmacokinetics and pharmacodynamics, long-term safety issues need to be addressed and that no comparison can be really made with those effects related to daily GH injections. The main safety concerns are the maintenance of supraphysiological elevation of GH throughout the day and non physiological tissue distribution. Besides, their potential advantages in terms of cost and compliance still need to be addressed in future clinical trials.

Theoretically GH replacement should be a lifelong treatment but the duration of treatment is still a matter

of debate. However if benefits are being achieved without any side-effect, there is no particular reason to stop treatment at a given age. On the other hand, regardless of the patient's age and condition, if no apparent benefit of treatment has been observed after 1 year, treatment withdrawal should be considered as the cost-effectiveness ratio becomes unbalanced (7,17,61).

SAFETY

1. SIDE EFFECTS

Most of the reported side effects are the result of GH-induced fluid retention and include edema, arthralgia, myalgia, paresthesia and carpal tunnel syndrome. They are observed early after GH therapy is initiated, they are more frequent with higher doses, and they subside following dose reduction. They occur in 5-18% of patients, more frequently in elderly, overweight and female patients (49, 65).

2. LONG TERM SAFETY

Given the potential role of GH and IGF-I in cell proliferation (66), the long-term safety of GH replacement therapy has been a concern and has therefore been well studied in several large epidemiological studies and post-marketing registries (67-69).

There is no evidence that treatment with GH increases the risk of recurrence of pituitary tumors (68-70), therefore the presence of a stable remnant of pituitary tumor is not a contraindication to GH treatment. Also, accumulating data do not suggest that GH administration to survivors of childhood cancer is associated with an increased risk of recurrence of the primary malignancy (71,72). However, it appears that there might be a slight excess risk of second neoplasia in GH treated patients compared with non GH treated cancer survivors, but the risk decreases with increasing length of follow-up (73). On the other hand results from large database are reassuring showing that there is no increased risk of "de novo" cancers in GH treated patients (68, 69). Although preliminary data from the French cohort of the 'Safety and Appropriateness of GH treatments in Europe' (SAGhE) study indicated an increased risk of overall mortality in adults treated with GH during childhood (74), the recent final results do not support that GH treatment affects the risk of cancer incidence or mortality and a causal relation is unlikely (75). Moreover, a recent review of available published data from GH registries, compiling data from real-life clinical practice and covering over 150,000 patients, provides reassurance on the long term safety of GH treatment (67). Nevertheless, continued surveillance of people exposed to GH is essential both during treatment and in the years thereafter, especially in the older people who elect to continue therapy (76). Moreover, an active neoplasia remains so far an absolute contra-indication to start or continue GH administration.

CONCLUSIONS

Adult patients with a confirmed GHD syndrome should be considered for replacement therapy. During the last 30 years, a large body of literature has accumulated and supports many important beneficial effects of GH on body composition, exercise capacity, skeletal mineralization and QoL. Treatment also improves several cardiovascular surrogates but has not been proved yet to reverse the increased vascular mortality associated with hypopituitarism. Most of the above results are sustained in the long-term (10-15 years) and the prevalence of serious adverse events is low. Based on the results from observational research studies, we can nowadays conclude

that GH therapy has a good safety profile when used for approved indications and at recommended doses.

However, a warning must be made here. With our better knowledge of the anabolic effects of growth hormone and the wider availability of unrestricted hormone quantities, including uncontrolled material provided by the black market and internet, its use (or misuse) is inevitably broadening, bypassing its so far evidence-based, well-accepted indications. Areas such as doping, body-building and anti-aging medicine are heavily contaminated by the fraudulent or inappropriate use of growth hormone or growth factors, and no one can predict today what will be the future consequences of this misappropriation of an otherwise safe and beneficial therapy.

RÉFÉRENCES

1. Li CH, Papkoff H. Preparation and properties of growth hormone from human and monkey pituitary glands. *Science* 1956;124:1293-1294.
2. Raben MS. Human growth hormone. *Recent Prog Horm Res* 1959;15:71-114
3. Glick SM, Roth J, Yallow RS, Berson SA. Immunoassay of human growth hormone in plasma. *Nature* 1963; 199:784-787.
4. Raiti S. Human growth hormone and Creutzfeldt-Jakob disease. *Ann Intern Med* 1985;103 (2): 288-289.
5. Jorgensen JO, Pedersen SA, Thuesen L *et al.* Beneficial effects of growth hormone treatment in GH-deficient adults. *Lancet*. 1989;1:1221-1225.
6. Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. *N Engl J Med*. 1989; 321:1797-1803.
7. Molitch M, Clemmons D, Malozowski S, Merriam G, Lee Vance M. Evaluation and treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2011; 96(6):1587-1609.
8. Stockholm K, Gravholt CH, Laursen T, Jørgensen JO, Laurberg P, Andersen M *et al.* Incidence of GH deficiency –a nationwide study. *Eur J Endocrinol*. 2006; 156:61-71.
9. Abs R, Bengtsson BA, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P *et al.* GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. *Clin Endocrinol* 1999; 50(6):703-713.
10. Hernandez LM, Lee PD, Camacho-Hubner C. Isolated growth hormone deficiency. *Pituitary*. 2007;10:351-357.
11. Melmed S. Idiopathic Adult Growth Hormone Deficiency. *J Clin Endocrinol Metab*. 2013; 98 (6): 2187-2197.
12. Tanriverdi F, Keleştimur F. Classical and non-classical causes of GH deficiency in adults. *Best Pract Res Clin Endocrinol Metab* 2017; 31: 3-11.
13. Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB *et al.* Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents : Growth Hormone Deficiency, Idiopathic Short Stature, and primary Insulin Like Growth Factor-I Deficiency. *Horm Res Paediatr* 2016; 86:361-397.
14. Boguszewski CL, Lacerda CS, Lacerda Filho Ld, Carvalho JA, Boguszewski MC. Reappraisal of serum insulin-like growth factor-I (IGF-1) measurement in the detection of isolated and combined growth hormone deficiency (GHD) during the transition period. *Arq Bras Endocrinol Metabol*. 2013 ; 57(9):709-716.
15. Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber A *et al.* Systematic Review: The safety and efficacy of Growth Hormone in the Healthy Elderly. *Ann Intern Med*. 2007; 146:104-115.
16. Clemmons DR, Molitch M, Hoffman AR, Klibanski A, Strasburger CJ, Kleinberg DL *et al.* Growth Hormone should be used only for approved indications. *J Clin Endocrinol Metab* 2014; 99 (2) 409-411.
17. Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. *Eur J Endocrinol*. 2007;157:695-700.
18. Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ. HypoCCS Advisory Board and U.S. HypoCCS Study Group. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? *J Clin Endocrinol Metab*. 2002; 87(2):477-485.
19. Steffens M., V. Beauloye, B. Brichard, Robert A, Alexopoulou O, Vermeylen Ch *et al.* Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). *Clin Endocrinol (Oxf)* 2008, 69:819-827.
20. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. *Endocr Rev*. 1998;19(6):717-797.
21. Kargi AY, Merriam GR. Diagnosis and treatment of growth hormone deficiency in adults. *Nat Rev Endocrinol*. 2013;9(6):335-345.

22. Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays--a 2009 update. *Growth Horm IGF Res*. 2010;20(1):8-18.
23. Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V *et al*. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. *J Clin Endocrinol Metab*. 2002;87(5):2067-2079.
24. Corneli G, Di Somma C, Baldelli R, Rovere S, Gasco V, Croce CG, *et al*. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. *Eur J Endocrinol*. 2005;153(2):257-264.
25. Dichtel LE, Yuen KC, Bredella MA, Gerweck AV, Russell BM, Riccio AD, *et al*. Overweight/Obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency. *J Clin Endocrinol Metab*. 2014;99(12):4712-4719.
26. Hoffman A.R., Kuntze JE, Baptista J, Baum HB, Baumann GP, Biller BM *et al*. Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. *J Clin Endocrinol Metab* 2004; 89 :2048-2056.
27. Appelman-Dijkstra NM, Claessen KM, Roelfsema F, Pereira AM, Biermasz NR. Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. *Eur J Endocrinol*. 2013; 169(1):R1-R14.
28. Elbornsson M, Götherström G, Bosæus I, Bengtsson BÅ, Johannsson G, Svensson J. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. *Eur J Endocrinol*. 2013; 168(5):745-753.
29. Götherström G, Bengtsson BA, Bosæus I, Johannsson G, Svensson J. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. *J Clin Endocrinol Metab*. 2007;92(4):1442-1445.
30. Arwert LI, Roos JC, Lips P, Twisk JW, Manoliu RA, Drent ML. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. *Clin Endocrinol (Oxf)*. 2005;63(3):310-316.
31. Widdowson WM, Gibney J. The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. *J Clin Endocrinol Metab*. 2008; 93(11):4413-4417.
32. Widdowson WM, Gibney J. The effect of growth hormone (GH) replacement on muscle strength in patients with GH-deficiency: a meta-analysis *Clin Endocrinol (Oxf)*. 2010;72(6):787-792.
33. Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. *J Clin Endocrinol Metab*. 2014;99(3):852-860.
34. Elbornsson M, Götherström G, Bosæus I, Bengtsson BÅ, Johannsson G, Svensson J. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. *Eur J Endocrinol*. 2012;166(5):787-795.
35. Appelman-Dijkstra NM, Claessen KM, Hamdy NA, Pereira AM, Biermasz NR. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. *Clin Endocrinol (Oxf)*. 2014 Nov;81(5):727-735.
36. Tritos NA. Focus on growth hormone deficiency and bone in adults. *Best Pract Res Clin Endocrinol Metab*. 2017; 31(1):49-57.
37. Mo D, Fleseriu M, Qi R, Jia N, Child CJ, Bouillon R *et al*. Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. *Lancet Diabetes Endocrinol*. 2015;3(5):331-338.
38. Mazziotti G, Doga M, Frara S, Maffezzoni F, Porcelli T, Cerri L *et al*. Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. *Endocrine*. 2016;52(1):103-10.
39. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS *et al*. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. *Lancet*. 2001; 357:425-431.
40. Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC *et al*. Mortality in patients with pituitary disease. *Endocr Rev*. 2010; 31(3):301-342.
41. Bengtsson BA. Untreated growth hormone deficiency explains premature mortality in patients with hypopituitarism. *Growth Horm IGF Res*. 1998; 8 Suppl A:77-80.
42. Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson BA, Göth MI *et al*. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database *Eur J Endocrinol* 2006; 155: 79-90.
43. Di Somma C, Scarano E, Savastano S, Savanelli MC, Pivonello R, Colao A. Cardiovascular alterations in adult GH deficiency. *Best Pract Res Clin Endocrinol Metab*. 2017; 31(1):25-34.
44. de Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. *Endocr Rev*. 1995;16(1):63-86.
45. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. *J Clin Endocrinol Metab*. 2004;89(5):2192-2199.
46. Monson JP, Jönsson P, Koltowska-Häggström M, Kourides I. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. *Clin Endocrinol (Oxf)*. 2007; 67(4):623-628.
47. Sesmilo G., Biller BM, Llevadot Hayden D, Hanson G, Rifai N, Klibanski A. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. *Ann Intern Med* 2000; 133 : 111-122.

48. Borson-Chazot F, Serusclat A, Kalfallah Y, Ducottet X, Sassolas G, Bernard S *et al.* Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. *J Clin Endocrinol Metab* 1999; 84: 1329-1333.
49. Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. *Circulation* 2003; 108: 2648-2652.
50. Nilsson AG, J. Svensson, G. Johannsson. Management of growth hormone deficiency in adults. *Growth Horm IGF Res* 2007; 17: 441-462.
51. Monson JP, Bengtsson BA, Abs R, Feldt-Rasmussen U, Wuster C. Can growth hormone therapy cause diabetes? KIMS Strategic Committee. *Lancet* 2000; 355: 1728-1729.
52. Rosen T, Wiren L, Wilhelmsen L, Wiklund I, Bengtsson BA. Decreased psychological well-being in adult patients with growth hormone deficiency. *Clin Endocrinol (Oxf)* 1994; 40:111-116.
53. Koltowska-Häggström M, Hebbest S, Mattsson AF, Monson JP, Kind P. Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary patients with growth hormone deficiency. *Horm Res* 2005; 64: 46-54.
54. Koltowska-Häggström M, Mattsson AF, Monson JP, Kind P, Badia X, Casanueva FF *et al.* Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? *Eur J Endocrinol* 2006; 155 : 109-119.
55. Murray RD, Shalet SM. Adult growth hormone replacement: lessons learned and future direction. *J Clin Endocrinol Metab* 2002; 87: 4427-4428.
56. Hazem A, Elamin MB, Bancos I, Malaga G, Prutsky G, Domecq JP *et al.* Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. *Eur J Endocrinol*. 2012;166(1):13-20.
57. Mo D, Blum WF, Rosilio M, Webb SM, Qi R, Strasburger CJ. Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study. *J Clin Endocrinol Metab*. 2014 ; 99(12):4581-4588.
58. Elbornsson M, Horvath A, Götherström G, Bengtsson BÅ, Johannsson G, Svensson J. Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency. *Eur J Endocrinol*. 2017;176(2):99-109.
59. Hernberg-Ståhl E, Luger A, Abs R, Bengtsson BA, Feldt-Rasmussen U, Wilton P *et al.* Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. KIMS International Board; KIMS Study Group. Pharmacia International Metabolic Database. *J Clin Endocrinol Metab*.2001 ;86(11):5277-5281.
60. Drake WM, Coyte D, Camacho-Hübner C, Jivanji NM, Kaltsas G, Wood DF *et al.* Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. *J Clin Endocrinol Metab*. 1998 ; 83 (11):3913-3919.
61. Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. *Endocr Pract*. 2009;15 Suppl 2:1-29.
62. Biller BM, Ji HJ, Ahn H, Savoy C, Siepl EC, Popovic V *et al.* 12-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency. *Pituitary*. 2013 ;16 (3):311-318.
63. Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L *et al.* Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency.Genentech Adult Growth Hormone Deficiency Study Group. *J Clin Endocrinol Metab*. 2005; 90(12):6431-6440.
64. Christiansen JS, Backeljauw PF, Bidlingmaier M, Biller BM, Boguszewski MC, Casanueva FF *et al.* . Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. *Eur J Endocrinol*. 2016; 174(6):C1-8.
65. Holmes SJ, Shalet SM. Which adults develop side-effects of growth hormone replacement? *Clin Endocrinol (Oxf)* 1995; 43 : 143-149.
66. Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. *Nat Rev Endocrinol*. 2011;7(1):11-24.
67. Stochholm K, Kiess W. Long-term safety of growth hormone. A combined registry analysis. *Clin Endocrinol (Oxf)*. 2017 Oct 21. doi: 10.1111/cen.13502.
68. Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL *et al.* . International HypoCCS Advisory Board. Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. *J Clin Endocrinol Metab*. 2013 ; 98(3):980-988.
69. Child CJ, Conroy D, Zimmermann AG, Woodmansee WW, Erfurth EM, Robison LL. Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study. *Eur J Endocrinol*. 2015 ; 172(6):779-790.
70. van Varsseveld NC, van Bunderen CC, Franken AA, Koppeschaar HP, van der Lely AJ, Drent ML. Tumor Recurrence or Regrowth in Adults With Nonfunctioning Pituitary Adenomas Using GH Replacement Therapy. *J Clin Endocrinol Metab*. 2015;100(8):3132-3139.
71. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G *et al.* Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. *J Clin Endocrinol Metab*. 2002 ;87(7):3136-3141.
72. Swerdlow AJ, Reddingius RE, Higgins CD, Spoudeas HA, Phipps K, Qiao Z *et al.* Growth hormone treatment of children with brain tumors and risk of tumor recurrence. *J Clin Endocrinol Metab*. 2000 ; 85(12):4444-4449.

RÉFÉRENCES

73. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W *et al.* Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. *J Clin Endocrinol Metab.* 2006 ;91(9):3494-3498.
74. Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G *et al.* Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. *J Clin Endocrinol Metab.* 2012 ; 97(2):416-425.
75. Swerdlow AJ, Cooke R, Beckers D, Borgström B, Butler G, Carel JC *et al.* Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study. *J Clin Endocrinol Metab.* 2017 ; 102(5):1661-1672.
76. Allen DB, Backeljauw P, Bidlingmaier M, Biller BM, Boguszewski M, Burman P *et al.* GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. *Eur J Endocrinol.* 2016 ; 174(2):P1-9.

CORRESPONDANCE

Dr. ORSALIA ALEXOPOULOU

Cliniques universitaires Saint-Luc
Service d'Endocrinologie et Nutrition
Avenue Hippocrate 10,
1200 Bruxelles
Orsalia.alexopoulou@uclouvain.be